Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tandem Diabetes Care (TNDM) EBIT Margin (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of EBIT Margin readings, the most recent being 2.86% for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 306.0% to 2.86% in Q4 2025 year-over-year; TTM through Dec 2025 was 18.45%, a 791.0% decrease, with the full-year FY2025 number at 18.45%, down 791.0% from a year prior.
  • EBIT Margin hit 2.86% in Q4 2025 for Tandem Diabetes Care, up from 9.17% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 6.07% in Q4 2021 to a low of 75.46% in Q1 2023.
  • Median EBIT Margin over the past 5 years was 9.93% (2024), compared with a mean of 14.54%.
  • Biggest five-year swings in EBIT Margin: crashed -6674bps in 2023 and later skyrocketed 5372bps in 2024.
  • Tandem Diabetes Care's EBIT Margin stood at 6.07% in 2021, then plummeted by -233bps to 8.06% in 2022, then tumbled by -121bps to 17.82% in 2023, then skyrocketed by 99bps to 0.21% in 2024, then skyrocketed by 1490bps to 2.86% in 2025.
  • The last three reported values for EBIT Margin were 2.86% (Q4 2025), 9.17% (Q3 2025), and 21.53% (Q2 2025) per Business Quant data.